A Stock Forecast 2025-2026
Distance to A Price Targets
A Price Momentum
10 Quality Stocks Worth Considering Now
Researching Agilent (A) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on A and similar high-potential opportunities.
Latest A Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, A has a neutral consensus with a median price target of $150.00 (ranging from $115.00 to $165.00). The overall analyst rating is Buy (7.8/10). Currently trading at $102.48, the median forecast implies a 46.4% upside. This outlook is supported by 10 Buy, 10 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 61.0% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 12.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
A Analyst Ratings
A Price Target Range
Latest A Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for A.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $135.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $115.00 |
| Feb 27, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $159.00 |
| Feb 10, 2025 | Barclays | Luke Sergott | Equal-Weight | Upgrade | $145.00 |
| Jan 27, 2025 | B of A Securities | Neutral | Maintains | $0.00 | |
| Jan 10, 2025 | Bernstein | Market Perform | Maintains | $0.00 | |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Neutral | Maintains | $150.00 |
| Dec 9, 2024 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $155.00 |
| Nov 27, 2024 | Barclays | Luke Sergott | Underweight | Maintains | $135.00 |
| Nov 26, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $160.00 |
| Nov 26, 2024 | Evercore ISI Group | In-Line | Maintains | $0.00 | |
| Nov 26, 2024 | Bernstein | Eve Burstein | Market Perform | Maintains | $135.00 |
| Oct 15, 2024 | Barclays | Luke Sergott | Underweight | Maintains | $145.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $145.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $157.00 |
| Aug 23, 2024 | Barclays | Luke Sergott | Underweight | Maintains | $135.00 |
| Aug 22, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $135.00 |
| Aug 22, 2024 | B of A Securities | Derik De Bruin | Neutral | Maintains | $147.00 |
| Aug 22, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $165.00 |
| Aug 22, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $160.00 |
Agilent Technologies Inc. (A) Competitors
The following stocks are similar to Agilent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agilent Technologies Inc. (A) Financial Data
Agilent Technologies Inc. has a market capitalization of $29.22B with a P/E ratio of 23.5x. The company generates $6.53B in trailing twelve-month revenue with a 19.3% profit margin.
Revenue growth is +1.4% quarter-over-quarter, while maintaining an operating margin of +23.2% and return on equity of +20.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Agilent Technologies Inc. (A) Business Model
About Agilent Technologies Inc.
Provides analytical instruments and solutions for life sciences.
Agilent Technologies generates revenue by offering a wide range of analytical instruments, software, services, consumables, and reagents tailored for life sciences, diagnostics, and applied chemical markets. The company primarily serves pharmaceutical, biotechnology, and government laboratories, positioning itself as an essential partner in research and development.
Founded in 1999 as a spin-off from Hewlett-Packard, Agilent Technologies is known for its strong focus on innovation in genomics, proteomics, and metabolomics. The company's products play a vital role in areas such as disease research, food safety, and environmental analysis, contributing significantly to advancements in public health and scientific understanding.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
17,900
CEO
Mr. Padraig McDonnell
Country
United States
IPO Year
1999
Website
www.agilent.comAgilent Technologies Inc. (A) Latest News & Analysis
Agilent Technologies' PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification as a Companion Diagnostic for identifying gastric or GEJ adenocarcinoma patients eligible for KEYTRUDA® treatment.
Agilent's IVDR certification for its PD-L1 assay enhances its market position in oncology diagnostics, potentially increasing revenue through partnerships with drug manufacturers like Merck.
Investors can utilize the Zacks Earnings ESP tool to identify stocks likely to exceed quarterly earnings estimates.
The Zacks Earnings ESP tool highlights stocks likely to exceed earnings forecasts, signaling potential investment opportunities and driving stock price appreciation.
Investor and consumer sentiment is low, suggesting a potential buying opportunity. GDP growth exceeds 2%, and inflation is declining, indicating a disconnect between sentiment and economic fundamentals.
Low investor sentiment suggests a potential buying opportunity, while strong GDP growth and falling inflation indicate economic resilience, creating a favorable environment for future gains.
Agilent Technologies (NYSE: A) supported Autolus Therapeutics in obtaining FDA approval for AUCATZYL®, a CAR T therapy, using its xCELLigence RTCA technology for potency assay development.
Agilent Technologies' involvement in a successful FDA approval for a CAR T therapy enhances its reputation in biotech, potentially increasing investor confidence and driving stock performance.
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
1 month agoAgilent Technologies awarded Columbia University an Agilent Research Catalyst Award for Dr. Pawel Muranski, a leader in bone marrow transplant and cancer immunotherapy research.
Agilent Technologies' partnership with Columbia University enhances its reputation in biotech, potentially driving innovation and attracting investments in cancer research and therapies.
Agilent Technologies Inc. (NYSE: A) will showcase its digital pathology solutions at the USCAP Conference in Boston, March 22-27, 2025, focusing on improving diagnostic accuracy and efficiency.
Agilent's participation in the USCAP Conference showcases its commitment to innovation in digital pathology, potentially boosting its market position and attracting investor interest in growth opportunities.
Frequently Asked Questions About A Stock
What is Agilent Technologies Inc.'s (A) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Agilent Technologies Inc. (A) has a median price target of $150.00. The highest price target is $165.00 and the lowest is $115.00.
Is A stock a good investment in 2025?
According to current analyst ratings, A has 10 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $102.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for A stock?
Wall Street analysts predict A stock could reach $150.00 in the next 12 months. This represents a 46.4% increase from the current price of $102.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agilent Technologies Inc.'s business model?
Agilent Technologies generates revenue by offering a wide range of analytical instruments, software, services, consumables, and reagents tailored for life sciences, diagnostics, and applied chemical markets. The company primarily serves pharmaceutical, biotechnology, and government laboratories, positioning itself as an essential partner in research and development.
What is the highest forecasted price for A Agilent Technologies Inc.?
The highest price target for A is $165.00 from Patrick Donnelly at Citigroup, which represents a 61.0% increase from the current price of $102.48.
What is the lowest forecasted price for A Agilent Technologies Inc.?
The lowest price target for A is $115.00 from Luke Sergott at Barclays, which represents a 12.2% increase from the current price of $102.48.
What is the overall A consensus from analysts for Agilent Technologies Inc.?
The overall analyst consensus for A is neutral. Out of 24 Wall Street analysts, 10 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $150.00.
How accurate are A stock price projections?
Stock price projections, including those for Agilent Technologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.